Literature DB >> 6189754

Development of the blood-CSF barrier.

A Statz, K Felgenhauer.   

Abstract

The development of the blood-CSF barrier was investigated by establishing total protein, individual protein levels and cell-counts in the CSF and serum of 185 healthy children, with an age range from 27 fetal weeks to 16 years. Albumin, alpha 2-macroglobulin and immunoglobulin G were found in all CSF specimens. With the exception of IgG, their concentrations decreased continuously until the end of the first year of life. IgM was not present in the CSF and IgA was found in only a few cases. Serum:CSF ratios of individual proteins increased continuously from the fetal period to the first year and there was a decline in barrier selectivity during the same period. Maturation of the barrier was maximal during the third month of life, decreasing quickly thereafter. The barrier condition of preterm infants was closely related to conceptional age, but not to the time of birth.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189754     DOI: 10.1111/j.1469-8749.1983.tb13738.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  12 in total

1.  Normative cerebrospinal fluid profiles in febrile infants.

Authors:  Carrie L Byington; Jeremy Kendrick; Xiaoming Sheng
Journal:  J Pediatr       Date:  2010-09-06       Impact factor: 4.406

2.  Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants.

Authors:  Samir S Shah; Jessica Ebberson; Lori A Kestenbaum; Richard L Hodinka; Joseph J Zorc
Journal:  J Hosp Med       Date:  2010-07-13       Impact factor: 2.960

3.  The measurement of CSF flow through the aqueduct in normal and hydrocephalic children: from where does it come, to where does it go?

Authors:  Grant A Bateman; Kirk M Brown
Journal:  Childs Nerv Syst       Date:  2011-10-27       Impact factor: 1.475

4.  Cerebrospinal fluid C-reactive protein in meningitis: diagnostic value and pathophysiology.

Authors:  E BenGershôm; G J Briggeman-Mol; F de Zegher
Journal:  Eur J Pediatr       Date:  1986-09       Impact factor: 3.183

5.  Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants.

Authors:  I Tessin; B Trollfors; K Thiringer; Z Thörn; P Larsson
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

6.  Cerebrospinal fluid reference ranges in term and preterm infants in the neonatal intensive care unit.

Authors:  Lakshmi Srinivasan; Samir S Shah; Michael A Padula; Soraya Abbasi; Karin L McGowan; Mary C Harris
Journal:  J Pediatr       Date:  2012-05-09       Impact factor: 4.406

Review 7.  The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history.

Authors:  Norman R Saunders; Jean-Jacques Dreifuss; Katarzyna M Dziegielewska; Pia A Johansson; Mark D Habgood; Kjeld Møllgård; Hans-Christian Bauer
Journal:  Front Neurosci       Date:  2014-12-16       Impact factor: 4.677

8.  Age-specific reference values for cerebrospinal fluid protein concentrations in children in southern China.

Authors:  Zhigang Liu; Deqin Jia; Jieming Dai; Xing Zhou; Zhoulian Qin; Liang Chen; Jieyan Zhang; Guohua Chen; Xiaocheng He; Ruipin Wan; Xingguang Ye
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

9.  Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.

Authors:  Marie-Christine Reinert; Pascal Benkert; Jens Wuerfel; Zuzanna Michalak; Esther Ruberte; Christian Barro; Peter Huppke; Wiebke Stark; Harald Kropshofer; Davorka Tomic; David Leppert; Jens Kuhle; Wolfgang Brück; Jutta Gärtner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-13

Review 10.  Recent progress and considerations for AAV gene therapies targeting the central nervous system.

Authors:  Erik Allen Lykken; Charles Shyng; Reginald James Edwards; Alejandra Rozenberg; Steven James Gray
Journal:  J Neurodev Disord       Date:  2018-05-18       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.